HSHannah M. Seagle

Hannah M. Seagle

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hannah M. Seagle has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Tables S1-S5 and Figures S1-S4 from Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer

    by Andreana N. Holowatyj, Wanqing Wen, Timothy Gibbs, Hannah M. Seagle, Samantha R. Keller, Digna R. Velez Edwards, Mary K. Washington, Cathy Eng, Jose Perea, Wei Zheng, et al.

    Table S1. Clinical and demographic characteristics of the colorectal cancer (CRC) patient study population by race/ethnicity and age at sequencing: AACR Project GENIE.Table S2. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with early-onset and late-onset nonhypermutated colorectal cancer. Genes ranked by false discovery rate (FDR).Table S3. Racial/ethnic patterns in baseline mutation probability, comparison and heterogeneity of all non-silent somatic gene mutations among patients with early-onset and late-onset non-hypermutated colorectal cancer.Table S4. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with earlyonset and late-onset non-hypermutated colorectal cancer by sex.Table S5. Read depth for clinical-grade targeting sequencing data from tumor tissues and case counts by early-onset and late-onset groups and sequencing center. Figure S1. Mutation rates among 6,903 tumor samples from colorectal cancer patients across racial/ethnic groups.Figure S2. Adjusted mutation rates in 653 hypermutated colorectal tumors: AACR GENIE.Figure S3. Tumor mutational burden (TMB) across sequencing assay/platform for early-onset and late-onset non-hypermutated colorectal cancer cases: AACR Project GENIE.Figure S4. Frequency of non-silent somatic mutations in commonly assayed and mutated genes between early-onset and late-onset non-hypermutated CRC cases (mutation frequency >10%).

  • Open Access

    Data from Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer

    by Andreana N. Holowatyj, Wanqing Wen, Timothy Gibbs, Hannah M. Seagle, Samantha R. Keller, Digna R. Velez Edwards, Mary K. Washington, Cathy Eng, Jose Perea, Wei Zheng, et al.

    Molecular features underlying colorectal cancer disparities remain uncharacterized. Here, we investigated somatic mutation patterns by race/ethnicity and sex among 5,856 non-Hispanic white (NHW), 535 non-Hispanic Black (NHB), and 512 Asian/Pacific Islander (API) patients with colorectal cancer (2,016 early-onset colorectal cancer patients: sequencing age <50 years). NHB patients with early-onset nonhypermutated colorectal cancer, but not API patients, had higher adjusted tumor mutation rates than NHW patients. There were significant differences for LRP1B, FLT4, FBXW7, RNF43, ATRX, APC, and PIK3CA mutation frequencies in early-onset nonhypermutated colorectal cancers between racial/ethnic groups. Heterogeneities by race/ethnicity were observed for the effect of APC, FLT4, and FAT1 between early-onset and late-onset nonhypermutated colorectal cancer. By sex, heterogeneity was observed for the effect of EP300, BRAF, WRN, KRAS, AXIN2, and SMAD2. Males and females with nonhypermutated colorectal cancer had different trends in EP300 mutations by age group. These findings define genomic patterns of early-onset nonhypermutated colorectal cancer by race/ethnicity and sex, which yields novel biological clues into early-onset colorectal cancer disparities.Significance:NHBs, but not APIs, with early-onset nonhypermutated colorectal cancer had higher adjusted tumor mutation rates versus NHWs. Differences for FLT4, FBXW7, RNF43, LRP1B, APC, PIK3CA, and ATRX mutation rates between racial/ethnic groups and EP300, KRAS, AXIN2, WRN, BRAF, and LRP1B mutation rates by sex were observed in tumors of young patients.See related commentary by Shen et al., p. 530.This article is highlighted in the In This Issue feature, p. 517


  • Open Access

    Genomics-informed drug-repurposing strategy identifies two therapeutic targets for preventing liver disease associated with metabolic dysfunction

    by Hannah M. Seagle, Alexis T. Akerele, Joseph A. DeCorte, Jacklyn N. Hellwege, Joseph H. Breeyear, Jeewoo Kim, Michael G. Levin, Samuel Khodursky, Adam Bress, Kyung Min Lee, et al.


  • Open Access

    Genomics-Informed Drug Repurposing Strategy Identifies Novel Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver Disease

    by Hannah M. Seagle, Alexis T. Akerele, Joseph A. DeCorte, Jacklyn N. Hellwege, Joseph H. Breeyear, Jeewoo Kim, Michael Levin, Samuel Khodurksy, Adam Bress, Kyung Lee, et al.

    Summary: Identification of drug-repurposing targets with genetic and biological support is an economically and temporally efficient strategy for improving treatment of diseases. We employed a cross-disciplinary approach to identify potential treatments for metabolic dysfunction associated steatotic liver disease (MASLD) using humans as a model organism. We identified 212 putative causal genes associated with MASLD using data from a large multi-ancestry genetic association study, of which 158 (74.5%) are novel. From this set we identified 57 genes that encode for druggable protein targets, and where the effects of increasing genetically predicted gene expression on MASLD risk align with the function of that drug on the protein target. These potential targets were then evaluated for evidence of efficacy using Mendelian randomization, pathway analysis, and protein structural modeling. Using these approaches, we present compelling evidence to suggest activation of FADS1 by icosopent ethyl as well as S1PR2 by fingolimod could be promising therapeutic strategies for MASLD.


  • Clinical Multigene Panel Testing Identifies Racial and Ethnic Differences in Germline Pathogenic Variants Among Patients With Early-Onset Colorectal Cancer

    by Hannah M. Seagle, Samantha R. Keller, Sean V. Tavtigian, Carolyn Horton, Andreana N. Holowatyj

    PURPOSE: The early-onset colorectal cancer (EOCRC) burden differs across racial/ethnic groups, yet the role of germline genetic predisposition in EOCRC disparities remains uncharacterized. We defined the prevalence and spectrum of inherited colorectal cancer (CRC) susceptibility gene variations among patients with EOCRC by race and ethnicity. PATIENTS AND METHODS: We included individuals diagnosed with a first primary CRC between age 15 and 49 years who identified as Ashkenazi Jewish, Asian, Black, Hispanic, or White and underwent germline genetic testing of 14 CRC susceptibility genes performed by a clinical testing laboratory. Variant comparisons by racial and ethnic groups were evaluated using chi-square tests and multivariable logistic regression adjusted for sex, age, CRC site, and number of primary colorectal tumors. RESULTS: Among 3,980 patients with EOCRC, a total of 530 germline pathogenic or likely pathogenic variants were identified in 485 individuals (12.2%). By race/ethnicity, 12.7% of Ashkenazim patients, 9.5% of Asian patients, 10.3% of Black patients, 14.0% of Hispanic patients, and 12.4% of White patients carried a germline variant. The prevalence of Lynch syndrome ( P = .037), as well as APC, CHEK2, MLH1, monoallelic MUTYH, and PTEN variants, varied by race/ethnicity among patients with EOCRC (all P < .026). Ashkenazim and Hispanic patients had significantly higher odds of presenting with a pathogenic APC variant, which included p.I1307K (odds ratio [OR], 2.67; 95% CI, 1.30 to 5.49; P = .007) and MLH1 variant (OR, 8.69; 95% CI, 2.68 to 28.20; P = .0003), respectively, versus White patients in adjusted models. CONCLUSION: Germline genetic features differed by race/ethnicity in young patients with CRC, suggesting that current multigene panel tests may not be representative of EOCRC risk in diverse populations. Further study is needed to optimize genes selected for genetic testing in EOCRC via ancestry-specific gene and variant discovery to yield equitable clinical benefits for all patients and to mitigate inequities in disease burden.


  • Open Access

    Supplementary Tables S1-S5 and Figures S1-S4 from Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer

    by Andreana N. Holowatyj, Wanqing Wen, Timothy Gibbs, Hannah M. Seagle, Samantha R. Keller, Digna R. Velez Edwards, Mary K. Washington, Cathy Eng, Jose Perea, Wei Zheng, et al.

    Table S1. Clinical and demographic characteristics of the colorectal cancer (CRC) patient study population by race/ethnicity and age at sequencing: AACR Project GENIE.Table S2. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with early-onset and late-onset nonhypermutated colorectal cancer. Genes ranked by false discovery rate (FDR).Table S3. Racial/ethnic patterns in baseline mutation probability, comparison and heterogeneity of all non-silent somatic gene mutations among patients with early-onset and late-onset non-hypermutated colorectal cancer.Table S4. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with earlyonset and late-onset non-hypermutated colorectal cancer by sex.Table S5. Read depth for clinical-grade targeting sequencing data from tumor tissues and case counts by early-onset and late-onset groups and sequencing center. Figure S1. Mutation rates among 6,903 tumor samples from colorectal cancer patients across racial/ethnic groups.Figure S2. Adjusted mutation rates in 653 hypermutated colorectal tumors: AACR GENIE.Figure S3. Tumor mutational burden (TMB) across sequencing assay/platform for early-onset and late-onset non-hypermutated colorectal cancer cases: AACR Project GENIE.Figure S4. Frequency of non-silent somatic mutations in commonly assayed and mutated genes between early-onset and late-onset non-hypermutated CRC cases (mutation frequency >10%).

  • Open Access

    Supplementary Tables S1-S5 and Figures S1-S4 from Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer

    by Andreana N. Holowatyj, Wanqing Wen, Timothy Gibbs, Hannah M. Seagle, Samantha R. Keller, Digna R. Velez Edwards, Mary K. Washington, Cathy Eng, Jose Perea, Wei Zheng, et al.

    Table S1. Clinical and demographic characteristics of the colorectal cancer (CRC) patient study population by race/ethnicity and age at sequencing: AACR Project GENIE.Table S2. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with early-onset and late-onset nonhypermutated colorectal cancer. Genes ranked by false discovery rate (FDR).Table S3. Racial/ethnic patterns in baseline mutation probability, comparison and heterogeneity of all non-silent somatic gene mutations among patients with early-onset and late-onset non-hypermutated colorectal cancer.Table S4. Baseline mutation probability, comparison and heterogeneity of non-silent somatic gene mutations among patients with earlyonset and late-onset non-hypermutated colorectal cancer by sex.Table S5. Read depth for clinical-grade targeting sequencing data from tumor tissues and case counts by early-onset and late-onset groups and sequencing center. Figure S1. Mutation rates among 6,903 tumor samples from colorectal cancer patients across racial/ethnic groups.Figure S2. Adjusted mutation rates in 653 hypermutated colorectal tumors: AACR GENIE.Figure S3. Tumor mutational burden (TMB) across sequencing assay/platform for early-onset and late-onset non-hypermutated colorectal cancer cases: AACR Project GENIE.Figure S4. Frequency of non-silent somatic mutations in commonly assayed and mutated genes between early-onset and late-onset non-hypermutated CRC cases (mutation frequency >10%).

  • Open Access

    Data from Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer

    by Andreana N. Holowatyj, Wanqing Wen, Timothy Gibbs, Hannah M. Seagle, Samantha R. Keller, Digna R. Velez Edwards, Mary K. Washington, Cathy Eng, Jose Perea, Wei Zheng, et al.

    Molecular features underlying colorectal cancer disparities remain uncharacterized. Here, we investigated somatic mutation patterns by race/ethnicity and sex among 5,856 non-Hispanic white (NHW), 535 non-Hispanic Black (NHB), and 512 Asian/Pacific Islander (API) patients with colorectal cancer (2,016 early-onset colorectal cancer patients: sequencing age <50 years). NHB patients with early-onset nonhypermutated colorectal cancer, but not API patients, had higher adjusted tumor mutation rates than NHW patients. There were significant differences for LRP1B, FLT4, FBXW7, RNF43, ATRX, APC, and PIK3CA mutation frequencies in early-onset nonhypermutated colorectal cancers between racial/ethnic groups. Heterogeneities by race/ethnicity were observed for the effect of APC, FLT4, and FAT1 between early-onset and late-onset nonhypermutated colorectal cancer. By sex, heterogeneity was observed for the effect of EP300, BRAF, WRN, KRAS, AXIN2, and SMAD2. Males and females with nonhypermutated colorectal cancer had different trends in EP300 mutations by age group. These findings define genomic patterns of early-onset nonhypermutated colorectal cancer by race/ethnicity and sex, which yields novel biological clues into early-onset colorectal cancer disparities.Significance:NHBs, but not APIs, with early-onset nonhypermutated colorectal cancer had higher adjusted tumor mutation rates versus NHWs. Differences for FLT4, FBXW7, RNF43, LRP1B, APC, PIK3CA, and ATRX mutation rates between racial/ethnic groups and EP300, KRAS, AXIN2, WRN, BRAF, and LRP1B mutation rates by sex were observed in tumors of young patients.See related commentary by Shen et al., p. 530.This article is highlighted in the In This Issue feature, p. 517

  • Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer

    by Andreana N. Holowatyj, Wanqing Wen, Timothy Gibbs, Hannah M. Seagle, Samantha R. Keller, Digna R. Velez Edwards, Mary K. Washington, Cathy Eng, Jose Perea, Wei Zheng, et al.

    Molecular features underlying colorectal cancer disparities remain uncharacterized. Here, we investigated somatic mutation patterns by race/ethnicity and sex among 5,856 non-Hispanic white (NHW), 535 non-Hispanic Black (NHB), and 512 Asian/Pacific Islander (API) patients with colorectal cancer (2,016 early-onset colorectal cancer patients: sequencing age <50 years). NHB patients with early-onset nonhypermutated colorectal cancer, but not API patients, had higher adjusted tumor mutation rates than NHW patients. There were significant differences for LRP1B, FLT4, FBXW7, RNF43, ATRX, APC, and PIK3CA mutation frequencies in early-onset nonhypermutated colorectal cancers between racial/ethnic groups. Heterogeneities by race/ethnicity were observed for the effect of APC, FLT4, and FAT1 between early-onset and late-onset nonhypermutated colorectal cancer. By sex, heterogeneity was observed for the effect of EP300, BRAF, WRN, KRAS, AXIN2, and SMAD2. Males and females with nonhypermutated colorectal cancer had different trends in EP300 mutations by age group. These findings define genomic patterns of early-onset nonhypermutated colorectal cancer by race/ethnicity and sex, which yields novel biological clues into early-onset colorectal cancer disparities. Significance: NHBs, but not APIs, with early-onset nonhypermutated colorectal cancer had higher adjusted tumor mutation rates versus NHWs. Differences for FLT4, FBXW7, RNF43, LRP1B, APC, PIK3CA, and ATRX mutation rates between racial/ethnic groups and EP300, KRAS, AXIN2, WRN, BRAF, and LRP1B mutation rates by sex were observed in tumors of young patients. See related commentary by Shen et al., p. 530 . This article is highlighted in the In This Issue feature, p. 517